Home › Studies › PRJNA1337442
PRJNA1337442 SRP630408

Azithromycin MDA & gut/nasopharyngeal resistome, Niger

Effect of Mass Azithromycin Distribution on Antibiotic Resistance in the Gut and Nasopharynx: A Cluster-Randomized Trial

450 samples from a cluster-randomized trial in Niger evaluating how twice-yearly mass azithromycin distribution to preschool children affects antibiotic resistance in the gut and nasopharyngeal microbiome. machine-written summary

450 samples · 450 runs · NE · Child · 2026 · 1.71 Gbp / sample

Sources
✓Sequence archive 450○Abstract / description✓Full text 450✓Supplementary tables 900–External resources–User contribution–Human verified

Checked this project's papers and archive records yourself? Mark it human-verified.

what each source gave
✓ Sequence archive450 sample values (country)
○ Abstract / descriptionread; no usable statement
✓ Full text450 sample values (collection date) · PMC13004693
✓ Supplementary tables900 sample values (sex, subject id)
– External resourcesnot covered by the external resources we ingest
– User contributionnothing uploaded yet · share metadata
– Human verifiednot yet checked by a person · I checked this project — verify it
Interventions

intervention — arms not resolved

Antibiotic given as the study intervention (incl. eradication therapy design randomized_controlled_trial · Azithromycin mass drug administration vs placebo, semiannual, 2 years

“cluster-randomized, placebo-controlled trial” — abstract:41845058 (study level; per-sample arms are in the intervention column below)

Samples at a glance
1 country
Age
unknown450
Sex
male243
female207
Country
NE450
Body site
excluded300
primary150
Sequencing depth per sample · this project all projects
all projects, 0–0.03 Gbp: 25,080 samples (4 %)all projects, 0.03–0.1 Gbp: 17,066 samples (3 %)all projects, 0.1–0.3 Gbp: 29,179 samples (5 %)all projects, 0.3–1 Gbp: 47,044 samples (8 %)this project, 0.3–1 Gbp: 141 samplesall projects, 1–3 Gbp: 124,983 samples (22 %)this project, 1–3 Gbp: 252 samplesall projects, 3–10 Gbp: 253,728 samples (44 %)this project, 3–10 Gbp: 56 samplesall projects, 10–30 Gbp: 72,533 samples (13 %)this project, 10–30 Gbp: 1 samplesall projects, 30–100 Gbp: 3,024 samples (1 %)all projects, 100–300 Gbp: 106 samples (0 %)all projects, ≥ 300 Gbp: 9 samples (0 %)project median 1.71 Gbp per sample0130Gbp
Sampling design and relatedness

community — not resolved

150 village-pooled rectal swab samples (~30 children per village pooled; one gut pool per village, AVENIR cluster-randomized MDA trial).

How longitudinal and relatedness information is derived

Community composition

No Sandpiper profile for this project's samples yet.

Field coverage
fieldsamplescoverageR1R2R3R4
age_category0 0%
country450 100%450
health_condition0 0%
subject_id450 100%450
collection_date450 100%450
sex450 100%450
Papers (1)
  • Mass azithromycin distribution and antibiotic resistance in the gut and nasopharynx: a cluster-randomized trial. PMID 41845058 PMC13004693 curated
Details
Archive description

Repeated twice-yearly azithromycin mass drug distribution (MDA) to preschool children reduced all-cause childhood mortality. However, the potential selection of antibiotic resistance (AMR) is a major public health concern as the program is being implemented in multiple countries in sub-Saharan Africa. This study evaluated the impact of azithromycin MDA targeting different age groups on the gut and nasopharyngeal microbiome and resistome of children in participating communities.

How this project entered the registry

Classified as human gut / stool / nasal / nasopharyngeal mixed assays of child and infant / toddler by sonnet_x2 with confidence 0.68. Assay mixed.

  • host run.host_tax_id · “9606”
  • body site study.title · “Gut and Nasopharynx”
  • life stage study.description · “azithromycin MDA targeting different age groups”
  • life stage study.description · “mass drug distribution (MDA) to preschool children”
Evidence examples (one per field × route)
samplefieldvaluerouteconf.sourcequote
SAMN52233313collection_date2023-05/2023-11R30.70paper.fulltext.methodsstarted on 20 May 2023 and ended on 23 November 2023
SAMN52233313countryNER10.90biosample_attrNiger
SAMN52233313sexmaleR20.75paper.supp.tablesex=Male
SAMN52233313subject_idchild_1106R20.75paper.supp.tablechild_id=child_1106
Sequencing

450 runs over 450 samples · mean 1.82 Gbp per run (median 1.71 Gbp, total 818.57 Gbp; 450 runs with a base count) · layout PAIRED 450 · platform ILLUMINA 450 · models Illumina NovaSeq X Plus (450) · 0% of runs with a Sandpiper profile · first public 2026-04-02

Authors (28)

Doan T first · Yan D · Arzika AM · Abdou A · Maliki R · Aichatou B · Bello IM · Beidi D · Galo N · Harouna N · Karamba AM · Mahamadou S · Abarchi M · Ibrahim A · Zhong L · Chen C · Liu Y · Yu D · Abraham T · Cheng AS · Peterson B · Oldenburg CE · Porco TC · Arnold BF · Hinterwirth A · Lebas E · O'Brien KS · Lietman TM last

Help complete this project

2 of the 4 core fields are below 50% coverage: age_category, health_condition. Share metadata

Downloads

PRJNA1337442.csv.gz (13.5 KB) · parquet (88.1 KB) — all 450 samples, every field with route and confidence · PRJNA1337442_determinations.csv.gz (10.8 KB) — 1,800 evidence rows

Samples (450 · every field this project has values for · hover a cell for its source)
Loading the sample table…